Artikelen door HollandBIO


WntResearch and SMS-oncology signed an agreement for the implementation of the phase II study with Foxy-5

SMS-oncology has been selected as the contract research organization (CRO) to conduct the phase II study with Foxy-5 in patients with colon cancer. WntResearch designed a clinical phase II trial with Foxy-5 as neoadjuvant therapy in colon cancer patients without evidence of metastases present. Their lead program Foxy-5, a small peptide that mimics the effects […]

Australia wants to GROW cotton that doesn’t wrinkle so people will stop relying on synthetic clothes that damage the environment

The dream of a cotton shirt that does not need ironing could one day materialise into a reality, with CSIRO scientists on the case. Researchers are examining what determines the length, strength and thickness of cotton fibres to see if a plant can be grown with the characteristics of a synthetic. ‘Cotton often gets a […]

Marine Biodegradable Plastic

BioLogiQ, recently announced that test results show its NuPlastiQ MB BioPolymer, produced by blending NuPlastiQ GP with PBAT (polybutylene adipate terephthalate), is marine biodegradable. Performed by Eden Research Laboratory, results show 97% biodegradation of a GP/PBAT film in ocean water within a one-year period, according to ASTM-D6691 standards for marine biodegradability. The key to this innovative new […]

HAL Allergy first company to achieve marketing authorisations in line with Therapieallergene Verordnung (TAV)

HAL Allergy announced the registration of SUBLIVAC® Birch 40.000 AUN/ml and SUBLIVAC® Trees 40.000 AUN/ml in Germany. These are the first marketing authorisations granted by the Paul Ehrlich Institute following the German Therapieallergene‑Verordnung (TAV).   The TAV was initiated by the German Federal Ministry of Health on 14 November, 2008, and regulates the marketing authorisation requirements for frequent therapeutic allergens, in […]

Abbott opent nieuwe fabriek in Weesp

Abbott opent woensdag officieel een nieuwe fabriek op haar productielocatie in Weesp. Met de opening van het nieuwe gebouw breidt de farmaceut de productie uit van dydrogesteron, een geneesmiddel dat wordt gebruikt om een progesteron-insufficiëntie bij vrouwen te behandelen. De nieuwe fabriek vertegenwoordigt een totale investeringswaarde van 80 miljoen Amerikaanse dollar en bevat dezelfde moderne […]

‘Niemand zal onze CRISPR-banaan willen’

Hoe de Europese regels rond genbewerking een poging om de banaan te redden torpederen. Het valt niet op wanneer je in de supermarkt langs de goed gevulde schappen loopt, maar het gaat niet goed met de banaan. Ziektes tasten wereldwijd plantages aan. Eet je een banaan, dan is dat doorgaans een Cavendish. Het gros van […]

FDA approves first-of-its kind targeted RNA-based therapy

The Food and Drug Administration approved Alnylam’s patisiran for the treatment of peripheral nerve disease (polyneuropathy), which is caused by hereditary transthyretin-mediated amyloidosis (hATTR). This is the first FDA-approved treatment for patients with polyneuropathy caused by hATTR, a rare, debilitating and often fatal genetic disease characterized by the buildup of abnormal amyloid protein in peripheral nerves, […]


Celebrating European Biotech Week 2018

EuropaBio is delighted to announce European Biotech Week 2018. Between 24 – 30th of September, the EU will, for the sixth time,  witness a week packed full of biotech-focused activities and events. European Biotech Week will be held alongside simlar initiatives, planned across 4 continents as part of Global Biotech Week. This year, we build […]

Boehringer Ingelheim takes its first step into gene therapy

The company have together with the UK Cystic Fibrosis Gene Therapy Consortium (GTC), consisting of Imperial College London and the Universities of Oxford and Edinburgh, Imperial Innovations, and Oxford BioMedica (OXB) announced a global collaboration to develop a first-in-class, long-term therapy for patients with cystic fibrosis (CF). The new partnership brings together the academic partners’ […]